NIR-activated HHC36-functionalized nanoparticles eradicate biofilms and heal infected diabetic wounds.
Background
The formation of bacterial biofilms at infection sites poses a significant barrier to the effective healing of diabetic wounds. These biofilm-associated infections are particularly challenging due to the rising prevalence of antibiotic-resistant strains and a scarcity of novel antibacterial agents. While photodynamic therapy (PDT) and antimicrobial peptides (AMPs) offer promising alternatives, each has limitations, such as the short half-life of PDT-generated reactive oxygen species (ROS). This research addresses the critical need for an alternative therapeutic platform that can overcome these challenges and effectively manage chronic wound infections.
Study Design
Researchers engineered polydopamine-HHC36-indocyanine green nanoparticles (PHI NPs) as an alternative to conventional antibiotics. These PHI NPs were synthesized by encapsulating indocyanine green (ICG), a phototherapeutic agent, within a polydopamine (PDA) matrix. The nanoparticle surface was then functionalized with the cationic antimicrobial peptide HHC36 for targeted pathogen binding. In vitro, PHI NPs demonstrated high-affinity binding to Staphylococcus aureus. For in vivo assessment, PHI NPs were administered intravenously to a murine diabetic wound model, where their accumulation at infected sites was monitored. Upon near-infrared (NIR) laser irradiation, the therapeutic efficacy was evaluated.
Results
PHI NPs exhibited high-affinity binding to Staphylococcus aureus in vitro, indicating selective pathogen targeting. Following intravenous administration in vivo, the nanoparticles effectively accumulated at infected sites within the murine diabetic wound model. Upon near-infrared (NIR) laser irradiation, a significant therapeutic effect was observed. The PHI NPs disrupted the complex biofilm architecture, subsequently eradicating the exposed bacteria through a synergistic mechanism. This synergy combined the photothermal and photodynamic effects of ICG with the direct antimicrobial action of HHC36. Notably, the bactericidal efficacy was robust and achieved under mild photothermal conditions, specifically below 45 °C, ensuring a favorable safety profile. This dual-action approach proved highly effective.
Key Findings
- PHI NPs bound
Staphylococcus aureuswith high affinity in vitro. - PHI NPs accumulated effectively at infected sites in a murine diabetic wound model.
- NIR laser irradiation disrupted biofilm architecture and eradicated exposed bacteria.
- Bactericidal efficacy resulted from synergy between phototherapy and HHC36.
- Eradication was robust under mild photothermal conditions (<45 °C), indicating a favorable safety profile.
Why It Matters
This research introduces a potent, biocompatible, and antibiotic-free strategy for combating biofilm-associated infections in diabetic wounds. The synergistic action of phototherapy and the antimicrobial peptide HHC36, delivered via targeted nanoparticles, offers a promising solution to the growing challenge of antibiotic resistance. This platform could revolutionize the treatment of chronic, non-healing wounds, particularly those complicated by multidrug-resistant bacteria, by providing a localized and highly effective intervention. While currently preclinical, this approach lays the groundwork for future clinical translation, potentially leading to novel protocols that avoid systemic antibiotic use and its associated side effects, improving patient outcomes for a vulnerable population.
hhc36
nanoparticles
diabetic-wounds
biofilms
antimicrobial
phototherapy